News

Discover the 'EU funding & me' mobile app launched by the Commission

Published on | 1 month ago

Programmes Horizon Europe Digital Europe EDF

Recently, the European Commission has launched 'EU funding & me', a new mobile app aiming to make EU funding simpler, smarter, and closer to people. The app is designed to provide the information of the EU Funding & Tenders portal in a personalised, mobile-friendly format.

The new app aims to offer the following services to users:

  • Navigate quickly to EU funding opportunities
  • Check the latest EU funding news and events
  • Save searches, subscribe to topics, and get personalised alerts
  • Receive real-time notifications
  • Integrate seamlessly with tools like calendars and share with one click
  • Check the real-time status of users’ proposals and projects
  • Exchange direct messages between project coordinators and project officers
  • Provide feedback directly to improve the app


You can download the app here: EU Funding & Tenders Portal . (Note that it is newly released & some glitches may still occur.)

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1786 articles available search in articles 

Testimonial

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.